| TTM
|
3/31/2026
|
3/31/2025
|
3/31/2024
|
3/31/2023
|
|
|---|---|---|---|---|---|
| Total Revenue
|
103,302 | 99,332 | 108,332 | 113,054 | 108,096 |
| Cost of Revenue
|
-46,764 | -44,922 | -51,748 | -53,540 | -48,058 |
|
Gross Profit
|
56,538 | 54,410 | 56,584 | 59,514 | 60,038 |
| Selling, General and Administrative Expenses
|
-40,345 | -39,417 | -36,150 | -38,437 | -42,164 |
|
Research and Development Expenses
|
-8,807 | -8,871 | -8,260 | -8,039 | -9,032 |
| Depreciation, Amortization and Depletion
|
-287 | -287 | -253 | -251 | -353 |
|
Operating Income/Expenses
|
-49,439 | -48,575 | -44,663 | -46,727 | -51,549 |
|
Total Operating Profit/Loss
|
7,099 | 5,835 | 11,921 | 12,787 | 8,489 |
| Total Net Finance Income/Expense
|
-5,049 | -5,201 | -8,195 | -13,364 | -13,606 |
| Net Investment Income
|
-693 | 247 | -1,068 | -83 | 844 |
| Irregular Income/Expenses
|
-3,745 | -3,155 | -1,218 | 766 | -768 |
|
Non-Operating Income/Expenses, Total
|
-9,487 | -8,109 | -10,481 | -12,681 | -13,530 |
|
Pretax Income
|
-2,388 | -2,274 | 1,440 | 106 | -5,041 |
| Provision for Income Tax
|
22 | -120 | 807 | -320 | 6,262 |
|
Net Income from Continuing Operations
|
-2,366 | -2,394 | 2,247 | -214 | 1,221 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
-2,366 | -2,394 | 2,247 | -214 | 1,221 |
|
Net Income after Non-Controlling/Minority Interests
|
-2,366 | -2,394 | 2,247 | -214 | 1,221 |
|
Net Income Available to Common Stockholders
|
-2,366 | -2,394 | 2,247 | -214 | 1,221 |
|
Diluted Net Income Available to Common Stockholders
|
-2,366 | -2,394 | 2,247 | -214 | 1,221 |
| Basic EPS
|
-0.07 | -0.07 | 0.09 | -0.01 | 0.06 |
| Diluted EPS
|
-0.07 | -0.07 | 0.08 | -0.01 | 0.06 |
|
Basic Weighted Average Shares Outstanding
|
32,209.83 | 32,316.78 | 25,821.87 | 22,321.45 | 19,976.17 |
|
Diluted Weighted Average Shares Outstanding
|
32,209.83 | 32,316.78 | 26,508.91 | 22,321.45 | 20,523.80 |
| Income Statement, Supplemental
|
|||||
|
EBIT
|
2,661 | 2,927 | 9,635 | 13,470 | 8,565 |
|
EBITDA
|
12,382 | 12,661 | 16,813 | 19,276 | 14,646 |
|
Normalized EBITDA
|
16,852 | 15,616 | 19,312 | 18,898 | 15,603 |
|
Normalized Income
|
2,062.82 | 117.75 | 4,371.15 | -535.30 | 1,927.17 |
|
Total Unusual Items
|
4,470 | 2,955 | 2,499 | -378 | 957 |
|
Total Unusual Items Excluding Goodwill
|
4,470 | 2,955 | 2,499 | -378 | 957 |
3/31/2023 - 1/9/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade